This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is BioNTech (BNTX) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
What's in the Cards for Sesen Bio's (SESN) Q2 Earnings?
by Zacks Equity Research
Sesen Bio's (SESN) Q2 performance is likely to reflect cost savings from the company's restructuring plans as the company continues to seek a potential partner for the further development of Vicineum.
Will AstraZeneca (AZN) Deliver a Beat This Earnings Season?
by Zacks Equity Research
Strong demand trends for AstraZeneca's (AZN) key drugs, Lynparza, Tagrisso, Imfinzi and Farxiga are likely to have driven the top line in the second quarter.
Pfizer (PFE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Revenues from the COVID-19 vaccine and COVID pill, Paxlovid are likely to have driven Pfizer's (PFE) sales in the second quarter.
Incyte (INCY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) top line is likely to have been driven by sales of its lead drug, Jakafi, in the second quarter.
Is a Beat in Store for Alkermes (ALKS) This Earnings Season?
by Zacks Equity Research
Alkermes' (ALKS) second-quarter 2022 results set to report earnings and revenues figures and provide updates on its portfolio of marketed drugs.
Centene (CNC) Gears Up for Q2 Earnings: What Lies Ahead?
by Zacks Equity Research
Centene's (CNC) second-quarter results are likely to reflect growth in premiums.
Teladoc Health (TDOC) Gears Up for Q2 Earnings: What Lies Ahead?
by Zacks Equity Research
Teladoc Health's (TDOC) second-quarter results are likely to reflect growth in Subscription Access Fees.
Gilead (GILD) Gets Positive CHMP Opinion for Veklury & Tecartus
by Zacks Equity Research
Gilead (GILD) receives positive CHMP opinion for full marketing authorization of its COVID-19 Jab, Veklury, and for using its CAR-T cell therapy Tecartus to treat relapsed or refractory B-cell precursor ALL in adults.
Merck (MRK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q2 earnings.
Vascular Biogenics (VBLT) Down, Ovarian Cancer Study Fails
by Zacks Equity Research
Vascular Biogenics' (VBLT) phase III OVAL study, evaluating ofra-vec in patients with platinum-resistant ovarian cancer, fails to meet the primary endpoint.
Merck's (MRK) Keytruda Head and Neck Cancer Study Fails
by Zacks Equity Research
Merck's (MRK) phase III KEYNOTE-412 study, evaluating Keytruda in earlier stages of unresected locally advanced head and neck squamous cell carcinoma, disappoints.
Sorrento (SRNE) Rises on FDA IND Clearance for COVID Drug
by Zacks Equity Research
Sorento Therapeutics (SRNE) receives IND application clearance from the FDA for a phase I study evaluating STI-1558 for COVID-19.
AstraZeneca (AZN) Enhertu Receives EU Nod for Expanded Use
by Zacks Equity Research
AstraZeneca (AZN) and partner Daiichi Sankyo's cancer drug, Enhertu, receives EU approval for use in adults with unresectable or metastatic HER2-positive breast cancer.
Novavax (NVAX) Up as CDC Endorses COVID Jab for Use in Adults
by Zacks Equity Research
Following the endorsement by the U.S. CDC, Novavax (NVAX) can now start immunizations with its COVID-19 vaccine as a primary two-dose regimen for use in adults in the United States.
Pfizer (PFE), BioNTech Seek EU Nod for Omicron-Based COVID Jab
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) complete a regulatory filing for their Omicron-specific bivalent COVID-19 vaccine in the EU. The bivalent vaccine has been developed to target the Omicron BA.1 subvariant.
Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down
by Zacks Equity Research
Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange for an upfront payment of $40 million.
Moderna's (MRNA) COVID Jab Gets Nod For Kids in Canada
by Zacks Equity Research
Moderna's (MRNA) mRNA-based COVID-19 jab, SpikeVax, receives approval from Health Canada for children aged six months through five years.
Will Biogen (BIIB) Succeed in Beating Q2 Earnings Estimates?
by Zacks Equity Research
Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the second quarter.
Novavax (NVAX) Down as EU Adds Side Effects to COVID Jab Label
by Zacks Equity Research
The administration of Novavax's (NVAX) COVID-19 vaccine leads to some cases of severe allergic reactions as well as skin problems, per a safety update issued by the EMA.
J&J (JNJ) to Begin Pharma Sector's Q2 Earnings With a Beat?
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above the market. In the MedTech segment, the recovery in demand trends seen in the first quarter is likely to have continued in the second.
Novavax's (NVAX) Protein-Based COVID Jab Gets EUA in the US
by Zacks Equity Research
Following the grant of emergency use authorization by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in the United States.
Novavax (NVAX) Inks COVID Jab Supply Deal With US Government
by Zacks Equity Research
Novavax (NVAX) inks a deal with the US government to supply 3.2 million doses of COVID shot. But the deal will be effective only if the vaccine gets EUA from the FDA. It also needs CDC recommendation.
Moderna (MRNA) Bivalent COVID Booster Effective Against BA.4/5
by Zacks Equity Research
Moderna's (MRNA) bivalent COVID booster candidate exhibits a higher antibody response against all-tested COVID-19 variants, including the Omicron subvariants BA.4 and BA.5.
Does BioNTech SE Sponsored ADR (BNTX) Have the Potential to Rally 48% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 47.9% in BioNTech SE Sponsored ADR (BNTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.